Dermatology Products · LP-089
Chlorhexidine Solution
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-089Dermatology Products
- Generic identity
- ChlorhexidineSolution
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-089
- Generic ingredient
- Chlorhexidine
- Dosage form
- Solution
- Proposed strength
- 0.05%; 4%; 5% concentrate
- Proposed pack
- Bottle 100 mL / 500 mL
- Portfolio category
- Dermatology Products
About Chlorhexidine
Chlorhexidine is an antiseptic used in different topical and oral formulations. The intended site and technique depend on concentration, solvent, excipients and the authorized product. The catalogue combines low-strength solution, stronger solution and a concentrate, which must not be treated as interchangeable. This educational profile does not establish Luang Pharma approved indications, an alcohol content, a dilution recipe or suitability for a particular anatomical site.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional selection must begin with a specific task, such as an authorized skin-preparation or cleansing use, and the correct formulation for that task. A skin antiseptic should not inherit mouthwash instructions. Concentrates require validated product instructions rather than improvised dilution. Clinical review also considers allergy history, age, skin condition and proximity to sensitive tissues. A general strength percentage is insufficient to determine safety for wound, eye, ear or neonatal use.
Important safety considerations
Chlorhexidine can cause immediate hypersensitivity, including anaphylaxis. A known or suspected prior reaction must be taken seriously. Eye exposure and contact with the middle ear or neural tissues can cause harm, and inappropriate neonatal use may cause chemical injury. Skin irritation is possible. Alcohol-containing products introduce additional flammability considerations, but this catalogue does not confirm the vehicle. Never use a concentrate directly or dilute it by guesswork; follow the exact authorized instructions.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue groups multiple chlorhexidine concentrations, including a concentrate. Each needs a separate intended-use description, vehicle and verified instructions. The concentration is not an application instruction, and a skin-preparation solution should not be substituted for a mouthwash, eye product or sterile irrigation solution.
Keep each concentration clearly labeled and segregated to reduce selection errors. Any dilution requires the authorized method, compatible materials and qualified personnel. Follow the actual storage, container and after-opening instructions. This page deliberately does not supply a dilution recipe or assume the presence of alcohol.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Chlorhexidine
- Dosage form / presentation
- Solution
- Catalogue strength
- 0.05%; 4%; 5% concentrate
- Catalogue pack
- Bottle 100 mL / 500 mL
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Source groups 0.05%, 4% and 5% concentrate without vehicle or specific use. Must be distinct presentations with authorized intended sites; never publish an assumed dilution recipe.
- P012 — One Solution record combines 0.05%, 4% and a 5% concentrate without specifying vehicles or intended sites by variant.
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: Chlorhexidine — clinical backgroundpublic-health medicine reference
- NHS: Chlorhexidine — side effectspublic-health medicine reference
- MHRA: Chlorhexidine — hypersensitivity warningregulatory safety communication
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Variant-specific chlorhexidine formulation records identifying vehicle, concentration, intended site/use and any authorised dilution instructions.
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-089, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
- NHS: Chlorhexidine — clinical background
- NHS: Chlorhexidine — side effects
- MHRA: Chlorhexidine — hypersensitivity warning
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-089.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.